Su Z, Zhao J, Xian G, Geng W, Rong Z, Wu Y, Qin C
Department of Hepatobiliary Surgery, Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, Shandong, China,
Clin Transl Oncol. 2014 Aug;16(8):702-7. doi: 10.1007/s12094-013-1136-8. Epub 2013 Nov 21.
Chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) is involved in malignancies. However, the role of CHD1L in gastric cancer (GC) has not been elucidated. The aim of this study is to explore the clinical role of CHD1L in GC.
The gene and protein expression levels of CHD1L were detected by quantitative real-time PCR and Western blot analysis in fresh samples of GC and paired adjacent noncancerous tissue (n = 34). We evaluated the CHD1L expression by immunohistochemistry in a large number of GC patients (n = 616) and paired adjacent noncancerous tissues from December 1, 2004 to December 1, 2008. The correlations of CHD1L expression with clinicopathological features and clinical outcome were analyzed.
The gene and protein expression levels of CHD1L were higher in fresh samples of GC than in paired adjacent noncancerous tissues as determined by quantitative real-time PCR and Western blot analysis. Immunohistochemical analysis showed that positive expression rates of CHD1L in GC and paired adjacent noncancerous tissues were 58.7 % (361/616) and 7.3 % (45/616), respectively. CHD1L positivity was significantly associated with clinical stage and distant metastasis. GC patients with positive CHD1L expression had shorter overall survival than those with negative CHD1L expression. Multivariate analysis showed that CHD1L was an independent prognostic marker for overall survival [Hazard Ratio (HR) = 5.952, 95 % confidence interval (CI) = 3.194-11.187, P = 0.0043].
These results indicated that CHD1L could serve as a prognostic marker for GC.
染色质结构域解旋酶/ATP酶DNA结合蛋白1样基因（CHD1L）与恶性肿瘤有关。然而，CHD1L在胃癌（GC）中的作用尚未阐明。本研究旨在探讨CHD1L在GC中的临床作用。
通过定量实时PCR和蛋白质印迹分析检测34例GC新鲜样本及其配对的癌旁非癌组织中CHD1L的基因和蛋白表达水平。我们采用免疫组织化学方法评估了2004年12月1日至2008年12月1日期间大量GC患者（n = 616）及其配对的癌旁非癌组织中CHD1L的表达情况。分析了CHD1L表达与临床病理特征及临床结局的相关性。
定量实时PCR和蛋白质印迹分析确定，GC新鲜样本中CHD1L的基因和蛋白表达水平高于配对的癌旁非癌组织。免疫组织化学分析显示，GC及配对癌旁非癌组织中CHD1L的阳性表达率分别为58.7%（361/616）和7.3%（45/616）。CHD1L阳性与临床分期和远处转移显著相关。CHD1L表达阳性的GC患者总生存期短于CHD1L表达阴性的患者。多因素分析显示，CHD1L是总生存期的独立预后标志物[风险比（HR）= 5.952，95%置信区间（CI）= 3.194 - 11.187，P = 0.0043]。
这些结果表明，CHD1L可作为GC的预后标志物。
